What Is CJC-1295 No DAC?
“CJC-1295 No DAC” is the common research-market name for Modified GRF 1-29, a short-acting analogue of growth hormone-releasing hormone, or GHRH.
GHRH is a natural hormone made by the hypothalamus that tells the pituitary gland to release growth hormone (GH).
Modified GRF 1-29 was designed to resist being broken down as quickly as natural GHRH while still acting through the same general signaling pathway.
The important part:
CJC-1295 No DAC is not the same thing as CJC-1295 with DAC.
That distinction matters a LOT when reading research.
What Does “No DAC” Mean?
DAC stands for Drug Affinity Complex.
The DAC version of CJC-1295 contains a chemical modification that allows it to bind to albumin in the blood, dramatically extending how long it remains active.
The No DAC form does not contain that albumin-binding modification.
So, conceptually:
CJC-1295 with DAC → prolonged GH/IGF-1 stimulation
CJC-1295 No DAC / Modified GRF 1-29 → shorter GH stimulation that is intended to behave more like a pulse
Most of the published human CJC-1295 research actually involves the DAC version, not the No DAC version.
That means results from CJC-1295 DAC studies should not automatically be applied to Modified GRF 1-29.
Why Are Researchers Interested in It?
The main area of interest is the growth hormone / IGF-1 system.
Growth hormone is involved in many biological processes, including:
- Growth and development
- Protein metabolism
- Fat metabolism
- Glucose regulation
- Bone biology
- Muscle biology
- Tissue repair
Growth hormone secretion also naturally occurs in pulses, with particularly strong pulses during sleep.
Modified GRF 1-29 is therefore studied as a way to stimulate the body’s own GH-releasing pathway rather than supplying growth hormone directly.
How Does It Work?
Modified GRF 1-29 acts on GHRH receptors in the pituitary gland.
The basic pathway is:
GHRH receptor stimulation → pituitary releases growth hormone → growth hormone influences tissues and stimulates downstream IGF-1 signaling.
That’s the simple version.
Rather than being growth hormone itself, Modified GRF 1-29 essentially sends a signal telling the pituitary to release GH.
The mechanism of the broader GHRH pathway is well established, but direct peer-reviewed human research specifically on the No DAC molecule is extremely limited.
Why Is It Often Paired With Ipamorelin?
You’ve probably seen these two mentioned together constantly.
There’s a biological reason.
Modified GRF 1-29 acts primarily through the GHRH receptor.
Ipamorelin acts through the ghrelin/GHS-R1a receptor.
They’re two different signaling pathways that can both stimulate growth hormone release.
That has led researchers and peptide-market users to explore them together, with the idea that stimulation through both pathways may produce a stronger GH signal than either pathway alone.
However, claims about specific outcomes from the CJC No DAC + Ipamorelin combination are much stronger online than the direct controlled human evidence.
What About Muscle Growth?
This is one of the biggest reasons people search for CJC-1295.
Growth hormone and IGF-1 clearly participate in muscle biology.
But that does not mean we have controlled clinical evidence showing that CJC-1295 No DAC reliably builds muscle in healthy people.
Claims involving:
- Muscle gain
- Faster muscle growth
- Increased lean mass
- Improved strength
- Body recomposition
are largely extrapolated from what we know about the GH/IGF-1 system, rather than demonstrated clinical outcomes for Modified GRF 1-29 itself.
What About Fat Loss & Metabolism?
Growth hormone participates in fat metabolism, which explains the research interest in body composition.
But again, mechanism and outcome are not the same thing.
There are no strong peer-reviewed human clinical trials demonstrating that CJC-1295 No DAC causes meaningful:
- Weight loss
- Belly-fat reduction
- Fat burning
- Improved body composition
in otherwise healthy adults.
Those are common marketing claims, not established clinical outcomes.
What About Recovery?
Growth hormone plays roles in tissue growth and repair, which is why CJC compounds are frequently discussed around:
exercise recovery, injury recovery and tissue repair.
That makes these reasonable areas for scientific investigation.
However, we do not have good clinical evidence proving that Modified GRF 1-29 speeds recovery from workouts or injuries in humans.
This is another place where the biological rationale is stronger than the direct evidence.
What About Sleep?
Natural growth hormone release is closely connected to sleep, with one of the largest GH pulses typically occurring during deep sleep.
That relationship has led to widespread claims that GHRH-related peptides improve:
- Deep sleep
- Sleep quality
- Recovery during sleep
The connection between sleep and GH physiology is real.
The evidence that CJC-1295 No DAC itself reliably improves sleep in humans is not established.
So sleep belongs in our research/search keywords—but not as a proven effect.
Evidence Snapshot
Established GHRH Biology: Strong
Related GHRH Human Research: Yes
CJC-1295 With DAC Human Research: Yes
CJC-1295 No DAC / Modified GRF 1-29 Direct Human Research: Essentially absent
Body Composition Outcomes: Not established
FDA Approved: No
Overall Evidence: Mechanistically plausible, but very limited direct clinical evidence
A 2026 review of growth-hormone-axis peptides rated CJC-1295 without DAC among the weakest evidence tiers because no peer-reviewed human studies directly evaluating the molecule were identified.
What Do We Know?
We know a great deal about the body’s GHRH → GH → IGF-1 signaling pathway.
We also know that modifying GHRH peptides can alter how resistant they are to enzymatic breakdown.
And human research on the separate DAC-containing version of CJC-1295 has shown that stimulating the GHRH pathway can substantially raise GH and IGF-1 levels.
Those findings make Modified GRF 1-29 scientifically plausible.
But plausibility is not the same as direct evidence.
What Don’t We Know?
We don’t have solid human evidence establishing that CJC-1295 No DAC:
- Builds muscle
- Causes meaningful fat loss
- Improves athletic performance
- Speeds workout recovery
- Repairs injuries
- Improves sleep
- Improves energy
- Reverses age-related changes
- Produces “anti-aging” effects
- Improves long-term health
Even some commonly repeated pharmacokinetic claims about the No DAC version are based on inference rather than direct peer-reviewed human measurement.
What About Safety?
Direct safety data for Modified GRF 1-29 specifically are very limited.
That matters because stimulating the GH/IGF-1 pathway can theoretically affect several systems throughout the body.
Potential concerns discussed around GH-axis stimulation include effects involving:
- Blood sugar regulation
- Fluid retention
- Joint or musculoskeletal symptoms
- IGF-1 elevation
- Cardiovascular signaling
But because the No DAC compound lacks robust controlled human studies, its actual short- and long-term risk profile has not been well established.
Research & Regulatory Status
CJC-1295 No DAC / Modified GRF 1-29 is not an FDA-approved medication.
It remains an experimental peptide encountered largely in research and gray-market settings.
One of the most important things when researching it is to confirm which molecule a source actually studied.
If the study used CJC-1295 DAC, it should not simply be presented as evidence for CJC-1295 No DAC.
Your Pep Resource Takeaway
CJC-1295 No DAC sounds straightforward until you start looking at the literature.
Then you discover that a huge amount of information online combines research from:
natural GHRH + sermorelin + CJC-1295 DAC + Modified GRF 1-29
as though they’re all the exact same compound.
They’re not.
The biological idea behind Modified GRF 1-29 makes sense: stimulate the body’s own growth-hormone-releasing pathway with a short-acting GHRH analogue.
But direct human evidence for the actual No DAC compound remains remarkably thin.
The mechanism is much better established than the outcomes people claim for it.
Research Areas / Search Keywords
CJC-1295 No DAC, CJC No DAC, CJC 1295 without DAC, Modified GRF 1-29, Mod GRF 1-29, Modified GHRH, growth hormone, GH, growth hormone release, low growth hormone research, growth hormone pulses, pulsatile growth hormone, GHRH, growth hormone releasing hormone, pituitary gland, pituitary health research, hypothalamus, IGF-1, hormone health, hormone optimization research, endocrine health, endocrine system, aging hormones, age-related growth hormone decline, anti-aging research, healthy aging, longevity research, muscle growth research, build muscle research, lean muscle research, lean body mass, muscle recovery, workout recovery, gym recovery, exercise recovery, athletic recovery, sports performance research, strength research, body composition, body recomposition, fat loss research, weight loss research, stubborn fat research, belly fat research, fat metabolism, metabolism, metabolic health, recovery, injury recovery research, tissue repair research, sleep, deep sleep research, sleep quality research, poor sleep, energy research, low energy research, CJC and Ipamorelin, CJC-1295 Ipamorelin, Ipamorelin combination, growth hormone peptides, GH secretagogues, peptide therapy research.
Educational Disclaimer: This profile is provided for educational and research-information purposes only. It is not medical advice and does not provide dosing, administration, treatment, or purchasing recommendations. CJC-1295 No DAC / Modified GRF 1-29 is not FDA approved, and direct human safety and effectiveness data are very limited.